Prophylactic Dose of Valacyclovir for Herpes Simplex
For chronic suppressive therapy of recurrent genital herpes simplex in immunocompetent adults, the recommended dose is valacyclovir 1 gram once daily, or 500 mg once daily for patients with 9 or fewer recurrences per year. 1
Standard Suppressive Dosing Regimens
The FDA-approved dosing options for daily suppressive therapy include 1:
- Valacyclovir 1,000 mg once daily (standard dose for most patients)
- Valacyclovir 500 mg once daily (alternative for patients with ≤9 recurrences per year)
- Valacyclovir 250 mg twice daily (less commonly used)
Important caveat: The 500 mg once-daily regimen is less effective in patients with very frequent recurrences (≥10 episodes per year), and these patients should receive higher doses. 2
Efficacy and Clinical Outcomes
Daily suppressive therapy reduces the frequency of genital herpes recurrences by ≥75% among patients with frequent recurrences (≥6 recurrences per year). 2
Key clinical trial data:
- In a large dose-ranging study of 1,479 patients, all valacyclovir dosages (250 mg once daily up to 1 g once daily) were significantly more effective than placebo at preventing or delaying recurrences, with a clear dose-response relationship. 3
- After 16 weeks of treatment with valacyclovir 500 mg once daily, 69% of patients remained recurrence-free compared to only 9.5% on placebo. 4
- Long-term studies have shown that 65-69% of patients remain completely recurrence-free during continuous suppressive therapy. 5
Special Populations
HIV-Infected Patients
For HIV-infected patients with CD4+ counts ≥100 cells/mm³, the recommended dose is valacyclovir 500 mg twice daily for chronic suppressive therapy of recurrent genital herpes. 1
Transmission Reduction
For immunocompetent patients specifically seeking to reduce transmission risk to an uninfected partner (with history of ≤9 recurrences per year), the dose is valacyclovir 500 mg once daily. 1 This regimen reduces transmission of symptomatic genital herpes by 75% and overall HSV-2 acquisition by 48% in heterosexual discordant couples. 6
Duration and Monitoring
Safety and efficacy have been documented for:
- Acyclovir: up to 6 years of continuous use 2
- Valacyclovir: documented for 1 year in the 1998 CDC guidelines, though more recent evidence supports longer-term use 2
After 1 year of continuous suppressive therapy, reassessment should occur to evaluate the patient's psychological adjustment and recurrence rate, as the frequency of recurrences naturally decreases over time in many patients. 2
Safety Profile
Suppressive therapy has not been associated with emergence of clinically significant acyclovir resistance among immunocompetent patients. 2
Valacyclovir is well tolerated at suppressive doses (500-1000 mg/day), with headache being the most commonly reported adverse effect. 7, 5, 4 The safety profiles of valacyclovir and placebo are comparable in clinical trials. 4
Clinical Pitfalls to Avoid
Do not use valacyclovir 500 mg once daily in patients with ≥10 recurrences per year – this dose is insufficient for very frequent recurrences and these patients require 1 gram once daily or 250 mg twice daily. 2
Suppressive therapy reduces but does not eliminate asymptomatic viral shedding, so patients should be counseled that transmission risk is reduced but not eliminated. 2
In rare cases of treatment failure with standard dosing, subtherapeutic acyclovir levels may be the cause; dose escalation or addition of cimetidine to enhance systemic acyclovir concentrations may be considered. 8